The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | RMC-9805: Phase I results in patients with KRAS G12D pancreatic ductal adenocarcinoma
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, discusses updated data for RMC9805, an allele-specific KRAS G12D inhibitor, in an expansion cohort for pancreatic cancer. Dr Spira highlights that the response rates are around 30%, but the clinical benefit rate, including partial and complete responses, as well as stable disease, is up to 80%, providing clear evidence of activity. Additionally, circulating tumor DNA (ctDNA) data shows significant clearance of KRAS G12D in patients, with 50% and 36% of patients experiencing at least 50% and complete clearance, respectively, This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
